Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28446519 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1725742 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15423480 | 0.75 | FAP (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25773837 | 0.68 | FAP (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27586900 | 0.68 | CES2 (0.35) | — | |
| N-Acetylproline SCHEMBL358379 | 0.66 | ACE (0.54) | — | |
| N-Acetylproline SCHEMBL428477 | 0.66 | ACE (0.54) | — | |
| N-Acetylproline SCHEMBL428476 | 0.66 | ACE (0.54) | — | |
| SCHEMBL13190988 | 0.66 | RAB9A (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3436833 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110358751-B | Recombinant lipase mutant, encoding gene, recombinant engineering bacterium and application | 浙江工业大学 | 2021-07-02 | — | — | CN | claimed |
| CN-109182298-B | Recombinant lipase mutant, engineering bacterium and application | 浙江工业大学 | 2021-05-11 | — | — | CN | claimed |
| CN-111518789-A | Recombinant lipase mutant, gene, vector and application thereof | 浙江工业大学 | 2020-08-11 | — | — | CN | claimed |
| CN-111518789-B | Recombinant lipase mutant, gene, vector and application thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-110358751-B | Recombinant lipase mutant, encoding gene, recombinant engineering bacterium and application | 浙江工业大学 | 2021-07-02 | — | — | CN | disclosed |
| CN-109182298-B | Recombinant lipase mutant, engineering bacterium and application | 浙江工业大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-109182298-B | Recombinant lipase mutant, engineering bacterium and application | 浙江工业大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-111518789-A | Recombinant lipase mutant, gene, vector and application thereof | 浙江工业大学 | 2020-08-11 | — | — | CN | disclosed |
| EP-2403831-B1 | SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLOÝ3,4-b¨PYRIDINE | ITALIANA SINT SPA (IT) | 2015-05-20 | — | — | EP | disclosed |
| US-8680276-B2 | Synthesis of (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2014-03-25 | — | — | US | disclosed |
| US-20110137036-A1 | SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137036-A1 | SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE | PDXK, OXA1L, PDK4 | CHRM2 2774/4885CHRM4 1456/4885CHRM5 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.